Although lack of efficacy is an important cause of late stage attrition in drug development the shortcomings in the translation of toxicities observed during the preclinical development to observations in clinical trials or postapproval is an ongoing topic of research. The concordance between preclinical and clinical safety observations has been analyzed only on relatively small data sets, mostly over short time periods of drug approvals. We therefore explored the feasibility of a big-data analysis on a set of 3,290 approved drugs and formulations for which 1,637,449 adverse events were reported for both humans animal species in regulatory submissions over a period of more than 70 years. The events reported in five species -rat, dog, mouse, rabbit, and cynomolgus monkey -were treated as diagnostic tests for human events and the diagnostic power was computed for each event/species pair using likelihood ratios.
Introduction
Analysis of the reasons for drug attrition in late development stages show that besides a lack of efficacy, failures in clinical safety which have not been adequately predicted in preclinical studies continue to be a major contributor (Waring et al., 2015) . The pivotal translational exercise to predict human adverse events is still mainly based on animal experimentation. Many of these animal models have been developed through long-standing experience and have been codified into international regulations. While experience has shown many animal models to be effective proxies for human there is still limited strict statistical evaluation of the human risk implied by observations in animal models, the main reason being the lack of sufficiently large and well curated preclinical and clinical data sets.
The history and the value of such concordance analyses has recently been summarized by Monticello et al. (2017) . Of primary importance is the improved understanding of the translatability of preclinical findings into human adverse events, which will facilitate the decision in early drug development, whether to continue or to stop a specific compound based on preclinical findings. It will also contribute to a critical assessment of current conduct of animal studies and study programs and eventually foster the search for new and better preclinical safety markers for those endpoints which show low concordance. Last but not least a thorough concordance analysis is also necessary for ethical reasons to justify the use of animals particularly since some authors claim a general lack of predictivity (Andrew Knight, 2007) , (Wall and Shani, 2008) , (Shanks et al., 2009) , (Bailey et al., 2014) .
One important study in the area of concordance analysis was carried out by Olson and coworkers using a curated set of 150 drug candidates and calculating the sensitivity, TP/(TP + FN), of the animal to human prediction (Olson et al., 2000) ,. The Olson publication has sparked numerous works investigating specific adverse events in more detail with various statistical methods to assess the concordance between animals and humans.
In their review of the original data from Fletcher. (1978) , Greaves et al. (2004) present true positive, true negative, false negative and false positive values for a small set of compounds (n = 45) and analyzed the species-specific concordance for different organ systems. One of the authors' conclusions is that the dog shows a better predictivity compared to rodents. Tamaki et al. compared the concordance of adverse drug reactions for 142 approved drugs and confirmed a concordance of more than 70% for hematological disorders, whereas musculoskeletal, respiratory and neurological ADRs showed a concordance of less than 30% (Tamaki et al., 2013) . Bailey et al. (2014) calculated Likelihood Ratios (LR's) for true positives for a data set of 2366 drugs for which animal and human data was available from FDA Adverse Event Reporting System [FAERS] , FDA NDAs and the DrugBank database (Wishart et al., 2017) . They concluded that the absence of toxicity in animals has very low predictivity for the lack of adverse events in humans. On the other hand, the presence of toxicity adds considerable evidence to occurrence of adverse events in humans evidenced by generally high positive Likelihood ratios (LR+), which indicates that a drug that is toxic in the investigated species is likely to cause adverse events in humans. However, the consistency of the LR+ between different classes of compounds and their effects was found to be low.
Focusing more specifically on individual endpoints such as QT prolongation Vargas et al. showed for a small set of compounds (n = 23) a 90% chance of predicting QT findings in humans through the use of a relevant non-rodent model (Vargas et al., 2015) . Mead et al. (2016) analyzed the concordance of Central Nervous System (CNS)-related safety concerns for 141 compounds based on the neurofunctional assessments in the "functional observational battery" or Irwin test (FOB/IT) (Mead et al., 2016) . The authors found that the five most common adverse events in Phase I clinical trials, namely headache, nausea, dizziness, fatigue/somnolence, and pain were not predicted by the FOB/IT.
The majority of animal-human concordance studies is based on assessment of true positives or true positive rate (TP/(TP + FN)), with limited analysis of the false positives. The fact that many animal positives cannot be distinguished between true or false because they are avoided by not progressing drugs to clinical trials is an inevitable reality of concordance analysis.
Previous work of the first author of this paper (Clark, 2015 ) studied a selected set of adverse events using the PharmaPendium database ("PharmaPendium, Reed Elsevier Properties SA," 2014), which contains preclinical safety and adverse event data collected from FDA and EMA submission documents, i.e. this data set is based on approved drugs over a time span of more than 70 years. The author correlated preclinical safety findings with adverse events for selected clinical MedDRA adverse classes for 3815 drugs, combining all species and studying a few classes of events. It was found that some nonclinical observations indicate higher risks for observing the same adverse event in clinical studies, particularly arrhythmias, QT prolongation, and abnormal hepatic function. On the other hand, the lack of these events in nonclinical studies was found to not be a good predictor of safety in humans, thus partly confirming the findings of Bailey et al. (2014) .
The present study is an extension of the previous approach now analyzing all events reported by the five most commonly used animal species and humans to create a database of concordances with statistical metrics. It is important to state that the present work did not attempt to use knowledge of the underlying mechanisms; it is a statistical evaluation combining the preclinical with the clinical data provided to regulatory bodies for drug approvals to investigate the feasibility of such an objective "big-data" approach.
With the advent of text mining and big-data evaluation methods we can now evaluate all events reported for all approved drugs and formulations to evaluate the current experience based on FDA and EMA regulatory filings. These filings provide an excellent data set because of the matched set of rigorously vetted animal and clinical trials for each drug. In contrast to Bailey et al. (2014) in our study we decided to exclude post-marketing events since these are reported via significantly less stringent criteria and conditions. It must be stated, however, that even if concordances can be quantified by a big data analysis, the most that can be concluded from observations that appear non-concordant between species is that some species are preferentially used for investigating specific endpoints not searched for in other species (e.g. phototoxicity is tested in rodents but not in dogs). In addition, many animal positive cases, be it true or false, are eliminated when animal observations prevent progress to clinical trial resulting in a skewed database. Since the FDA/EMA data set includes only information on drugs which are or had been approved, it represents a selection with intentionally limited severity of human observations.
Our study intends to address the following questions:
• What is the positive concordance of an observation in an animal with adverse events reported from clinical trials?
• Is the positive concordance, i.e. the translatability of an observation for animal-to-human dependent on the animal species used?
• Can the positive concordance be increased by looking at higher level groupings of the observations above the preferred term level?
The study also aimed at answering the question in how far such a big data approach is feasible and more efficient than the cumbersome data collection, curation, and analysis in previous published concordance analyses.
Answers to the above questions can be valuable for:
• guiding the selection of species for studies by assessing the predictive power of that species for the anticipated observation,
• referring to the risk implied by the observation based on experience using strong statistical criteria,
• and enhancing the evaluation of the potential clinical risk based on specific animal observations.
Methods

Data
The Elsevier PharmaPendium database was used as the source of preclinical safety-related observations as well as adverse events recorded in clinical trials and reported in drug approval filings ("PharmaPendium, Reed Elsevier Properties SA," 2014). PharmaPendium currently contains 1,637,449 adverse event reports for 3920 drugs and drug formulations and spans a period of drug approvals of more than 70 years (see Supplementary Material, which also contains an example, how the preclinical data is structured in PharmaPendium). The database has no limitations about indications and covers both small molecules as well as other modalities ("biologics"). The data is mined in a semi-automated manner (including human curation) from FDA and EMEA documents released in connection with drug approvals, and is supplemented by data from Mosby's Drug Consult and Miller's Side Effects of Drugs. (Mosby's Drug Consult 13th Edition, 2003) , (Dukes, 1992) The text mining identifies if the study authors stated for example that the alanine aminotransferase (ALT) was raised and identified as an adverse event. Naturally many reports measure and report ALT levels, but the adverse event record in PharmaPendium is generated only if the study authors conclude that there was a notable increase, i.e. likely treatment related. That is the indexing uses the conclusions and statements made by the study director to the FDA to conclude whether the ALT was significantly increased above normal levels.
The adverse events are coded to MedDRA preferred terms by the PharmaPendium curators. (Brown et al., 1999) . Only reports from controlled clinical studies were used, i.e. post-marketing adverse event reports (e.g. FDA's FAERS) were not included in this study because these pharmacovigilance data contain numerous confounders (e.g. comorbidity, reporting bias) which are difficult to control. The scale of the approach means that some erroneously interpreted observations will be included from the 1.6 million, but the hope is that the tests for statistical significance will determine if the signal is above the noise level. Unlike previous concordance studies, the original data for each adverse event report for animal and human can be identified and evaluated by the community by linking to the approval document where it was reported. Table 1 ranks the top ten species (including humans) according to the counts of observations reported in regulatory submission documents in PharmaPendium. For this study the top 5 preclinical species, i.e. rat, dog, mouse, rabbit, and cynomolgus monkey were used for concordance analysis with human adverse events.
Aggregation of reports into higher level categories
The concordance analysis evaluated whether a safety-related observation was recorded in both an animal species and human. Since the events are recorded at the MedDRA preferred-term level we also were interested in grouping events to examine concordance at the higher levels of high-level terms, high-level group terms, and system organ class terms (see Table 4 as an example for such a grouping; an example, how the grouping effects contingency table results can be found in the Supplementary Material) to assess the utility and statistical significance of such relationships. The sums were computed based on any observation in the same category. For example, for cardiac disorders a true positive is counted for a drug if it had any event under that organ class (e.g. ventricular tachycardia) and the animal had any event in that category even if it was not the same event. (e.g. bradycardia).
Concordance metrics
Animal-human concordance relationships were evaluated via 2 by 2 contingency tables for each species-observation pair. We treated the animal observation as a diagnostic test for the clinical observation and used the statistical methods developed for evaluation of the efficacy of diagnostic tests.
The values in the 2 by 2 contingency table, which are counts of number of compounds in each of the four categories for a given biomedical observation or MedDRA class of observations, were generated as follows and shown in Fig. 1 for every unique observation recorded in either human or animal.
The true negative (TN) values were counted as observations not made in either human or animal. This is an estimate since not all possible observations were measured or attempted to be observed for every drug.
In our study we use the positive likelihood ratio, "LR+", computed with the formula TP*(FP + TN)/FP*(TP + FN) from the values in Fig. 1 to express the statistical connection between animal and clinical observations. (Grimes and Schulz, 2005) , (McGee, 2002) The likelihood ratio represents the change in clinical risk when the adverse event is observed in an animal study. The likelihood ratio has the advantage that it is independent from the prevalence (Bayesian prior probability) for each observation so that it is more comparable across different adverse events than the conditional probability or positive predictive value. (Chien and Khan, 2001) . In this study, we use LR+ 10 or greater as a cut-off for strong concordance. The negative likelihood ratio, "LR-", which represents the decrease in risk if the animal observation is not made was also computed (Altman et al., 2000) .
A subjective interpretation of the likelihood ratio is given in Table 2 according to (Chien and Khan, 2001) , where generally speaking higher positive likelihood ratios indicate more reliable correlations than low values. The statistical significance was measured by the Yates-corrected chi-squared metric (Yates, 1934) . The chi-squared test measures whether there is a statistically significant relationship of any kind between the animal and human observation. Unless otherwise noted only relationships at or above the 99% confidence level are discussed. The likelihood ratio measures the predictive value of the animal observation. If the chi-squared is high, and the likelihood ratio is low, one can state that there is a high confidence that the animal observation does not predict a human observation.
Results
Overview of contingency metrics results
Contingency tables were calculated for each of the ca 9000 adverse events and each of the 5 animal-human pairs, creating about 50,000 tables. This was repeated for the higher level MedDRA terms that collect the underlying terms. Table 3 provides some examples for these table selected based on high TP values (further examples can be found in the Supplementary Material).
Overall true positive rates
The overall sum of true positive adverse events grouped by MedDRA system organ class and species is shown in Fig. 2 . The distribution of events of the different organ class within a species is shown in Fig. 3 .
The counts show that concordant events are not evenly distributed among either the species or organ classes. The class with the highest total number of true positive concordances is "gastrointestinal disorders" in the dog, with "general disorders and administration site conditions" in the ratfollowing close behind. Fig. 3 shows how the events are distributed in the organ classes normalized so that the wedges for each species sum to 100%. This percent distribution illustrates on the one hand the fact that some species are used specifically for testing particular endpoints, e.g. nearly Table 2 Subjective interpretation of positive likelihood ratios (Chien and Khan, 2001 ).
LR+ Interpretation
> 10 large and often conclusive shifts in probability 5-10 moderate shifts in probability 2-5 small, but sometimes important, shifts in probability 1-2 Alters probability to a small, and rarely important, degree 25% of all rabbit TP observations fall into the administration site reaction organ class, reflecting the use of rabbits for testing local tolerability on skin, eye, and injection site. On the other hand, it also confirms the documented sensitivity of species for specific endpoints, e.g. for dogs where 23% of TP observations are gastrointestinal disorders, and 17% are cardiac. In order to be able to distinguish between percent TP distribution and the frequency of use of an individual species to test for specific endpoints and organ classes Fig. 4 displays the percent distribution adjusted for the frequency of species use.
The highest rates of true positives normalized for frequency of animal use is observed for rats and dogs, the dog showing higher TPs particularly for cardiac and gastrointestinal disorders, whereas the rat has higher values for renal and urinary, respiratory, thoracic & mediastinal disorders, as well as surprisingly for endocrine disorders.
Overall statistics for grouping into higher level MedDRA categories
The analysis of all reported human-animal-event combinations results in thousands of relationships. We therefore prioritized the reported overall results by limiting them to those relationships that were statistically significant for each grouping. For each grouping level the number of animal-human concordances with positive likelihood ratios greater than 10, and significant at the 99% confidence level were counted. The MedDRA grouping levels are preferred terms (PT), highlevel terms (HLT), high-level group terms (HLGT), and system organ class (SOC) (Brown et al., 1999) . PharmaPendium observations are recorded at the preferred term level. Few statistically significant relationships remained when results were summarized to the system organ class (SOC) MedDRA classification level because of the combination of the FN, FP values as well as the TP values. The number of statistically significant events at each level is shown in Table 4 .
In a next step, we looked at specific endpoints in more detail and the effects of aggregating data according to MedDRA levels. Table 5 shows the statistical effect of looking at QT prolongation at increasing levels of the MedDRA hierarchy. At the preferred term level, there are 69 drugs with the effect observed in animal and human and a likelihood ratio of 10.7, i.e. indicating large and often conclusive shifts in probability of observing the adverse event in humans if reported in animals. At the parent level, "ECG investigations", there are more concordant events but the likelihood ratio is lower due to the increased inclusion of other members of the sub-category with more false positives and negatives. Fig. 5 illustrates the 341 separate reported preferred terms that are combined in the statistical analysis for the high-level group term cardiac and vascular investigations.
As one then looks at the parent high-level group term the dilution effect increases due to the large number of preferred terms that roll up to the high level group term. The likelihood at this level is much less predictive at 4.29. In Tables 5 and 6 the column TP provides the number of drugs for which a specific observation was recorded in both human and animal to provide a reference for the overall magnitude of concordance. Each successive row is the parent classification of the previous row. The effect "Electrocardiogram QT prolonged" is grouped with 67 other electrocardiogram parameters such as PQ, PR, PRS, QRS and other intervals into the high-level term "ECG investigations". "ECG investigations" is one of 10 high level terms, along with cardiac imaging procedures, vascular imaging and others that come under the high-level group term "Cardiac and vascular investigations (excl enzyme tests)." Table 6 lists the most prevalent statistically significant and predictive (LR+ > 10) events predicting human observation combined for all species. 3.5. Comparison of concordance of events across species Fig. 7 shows events at the preferred term level connected by human concordance for the five-animal species, filtered at the 99.99% confidence level, 5 or more true positive drugs, and likelihood ratio ≥ 10 to reduce complexity. The line thickness is proportional to the positive likelihood (LR+) ratio of the animal-human concordance. The line darkness is proportional to the number of true positives.
Most concordant observations for all species
The figure immediately reveals some strengths and weaknesses of the chosen method. Some of the concordances with particularly high LR + and prevalence values confirm wide-spread empirical experience of toxicologists, e.g. the clinical observation of somnolence in monkeys is considered to be predictive for the human (Balzamo et al., 1977) as well as it is known that skin disorders observed in monkeys often also occur in humans particularly for oncology drugs (Bugelski and Martin, 2012) . Another example is arrhythmia, which shows a high concordance in dog and rabbit. Whereas the telemetered dog is a known predictive species for cardiovascular events in human (Ewart et al., 2014; Vargas et al., 2015) , the rabbit contributes to this good concordance not only due to the reported response to hERG inhibition (Vargas et al., 2015) , but evidently also due to the use of ex vivo rabbit studies with Langendorff isolated hearts and Purkinje fibers (see example in Fig. 6 from the original report).
The rather strong concordance of the observation of "drug specific antibodies present" between mouse and monkey most probably reflects the preferential selection of transgenic mice (or wild-type mice using the murine surrogate) and non-human primates for assessing proteinbased drugs ("biologics") (Bussiere, 2008) . The same holds true for topical effects on eye and skin showing a high concordance in the rabbit. As already mentioned further above this concordance is most probably driven by the fact that these specific endpoints have been in the past preferentially investigated in the rabbit ("Draize test" for skin or eye corrosion or irritation). In summary, this graphical analysis thus shows on the one hand that the concordance between animal species and human is dominated by the selection of species for a specific safety endpoint. On the other hand, it shows that the selected species is Fig. 3 . Distribution of true positives by system organ class and species. Fig. 4 . Distribution of true positives by system organ class and species, normalized by proportion of true positives in each species for each organ class. predictive for the endpoint of interest. Table 7 shows the top 5 events by TP count observed at the 99% confidence level and likelihood ratios ≥ 10 for each species separately. The high likelihood ratio suggests that observation of each of these events in animal models suggests a high risk for an observation in human. The TP value corresponds to the number of drugs with the observation in both animal and human from Fig. 1 .
Most concordant animal models by species
As already indicated above, some of the concordances with high TP values and positive likelihood ratio are triggered by the almost exclusive use of an specific animal species for these endpoints as can be illustrated again for the rabbit: except for blood creatinine increase it can be postulated that all other high concordance values for the observation of conjunctival hyperaemia, mydriasis, injection site erythema and injection site reaction in rabbits are actually due to the long standing specific usage of this species for testing skin and eye tolerability. On the other hand, the high TP and LR+ values confirm the predictive value of this species for these endpoints. Table 8 shows events that occur frequently in both human and animal (from all species combined) and are statistically significant but have low positive likelihood ratio, i.e. low predictive value.
Events with low predictive value
Discussion
Overview
We performed a statistical analysis of a large number of drug submission documents supported by text mining by correlating 1,637,449 adverse event reports for 3920 drugs and formulations from EMA and FDA submission documents and analyzing the concordance between preclinical and clinical safety-related observations using contingency tables and likelihood ratio calculations. The likelihood ratio, LR+, is a robust indication of the human risk implied by an animal observation as the diagnostic. The inverse negative likelihood ratio (1/LR-) measures the human impact of not observing an event in an animal study. In nearly all cases the LR-value is close to 1 meaning that in a statistical sense the lack of an animal observation does not imply a lower risk for human. The few examples where the calculation of 1/LR-resulted in values of > 10 are listed in Table 9 . Our finding that absence of animal toxicity is of limited predictivity for the lack of adverse events in humans was already reported in previous studies (Clark, 2015) , (Bailey et al., 2014) .
In general, highly prevalent observations provide better statistical sampling and those considered to be medically the most critical ones are prevalent because they are the object of intense study both preclinically and clinically. The observations in Fig. 7 were filtered for relationships at the 99.99% confidence level, and the true positive (TP) drugs in human and animal greater than 6, and LR+ ≥ 10 to focus on the most significant relationships. The graph illustrates which observations are significant at this level across several species. Some observations appear to be more unique to single species. For example photosensitivity is unique to mouse likely because in vivo toxicity studies are almost exclusively carried out on mice. The same is true of iritis and other ocular observations in rabbit, the most common species used in the past for eye studies ("Draize test"). In general, the most prevalent and predictive rabbit observations deal with eyes (conjunctival hyperaemia, mydriasis) and injection site reactions although these are also significant for monkey and mouse. Several cardiac observations are unique to dog at this filtering level, reflecting the preferred use of that species for many cardiac studies.
Some of the statistically significant concordances with the highest true positive (TP) findings did not have high likelihood ratios. These include in dog, vomiting, diarrhoea, and alanine aminotransferase (ALT) increased. The positive likelihood ratios for these observations range from 5.4 to 7.8 which suggest only moderate risk for human. The concordance for ALT increase is also statistically significant but of only medium likelihood when observed in rat, mouse, and rabbit. The observation of ALA increase is impactful for cynomolgus monkey, however, with LR+ of 16.3. While statistically significant, the relatively high number of false negatives -observation in human but not animaldecreases the predictive power.
A surprising finding of our analysis was that constipation is among the most prevalent and predictive observation in common among rodents and humans (most often reported as 'decreased fecal output' in rats). It is also statistically significant for dog, with a LR+ of 8.1 from 33 drugs, but less common compared to rodents.
Comparison to other reports
The Olson study computed sensitivity, TP/(TP + FN), as the metric of concordance, which includes the false negative count. In the context of this study this is represented by the negative likelihood, which in nearly all cases is very close to 1.0, suggesting that the lack of animal observation does not generally predict safety in human. The selectivity computed for all species and organ classes combined is 7%, which is generally lower than reported in the Olson study. For example, Olson reported 90% sensitivity for liver disorders, while in this study the value is 16%. The main reason for this discrepancy is the fact the Olson's data set significantly differs from the PharmaPendium data set, the former being development candidates, some of them (37%) stopped due to safety reasons, whereas PharmaPendium represents mainly marketed drugs which passed the rigorous clinical safety testing. In the recent study by Monticello referring to 182 drugs a lower sensitivity than Olson, but with 48% higher than this study was reported (Monticello et al., 2017) . The overall positive and negative concordance at the system organ class level is shown in Table 10 (additional tables with further SOCs and subgroups of liver observations can be found in the Supplementary Material) with positive predictive values (PPV) and negative predictive value (NPV) as computed by Monticello. These values show a good positive predictive value, but poor negative predictive value. As discussed we feel that this is due to the inclusion of many preferred terms nominally grouped under this organ class in MedDRA. This conclusion is strengthened by evaluation of some major hepatobiliary toxicities in dog at the preferred-term level, shown in Table 11 . Table 11 shows that for individual major terms the negative predictive value can be quite good. This may be the result of systematic inclusion of all sub-categories, where the Monticello used more human selected subcategories in their grouping of events to the organ class level. In addition, this work uses a substantially larger number of drugs than Monticello. An early study by Fletcher (1978) found a high concordance for vomiting and gastrointestinal issues based on true positive values. This work also finds a large number of true positives (TP) for these events in both animals and human. These are the most prevalent observations from that standpoint. However, a high rate of false positives and negatives results in likelihood ratios of 5.7 and 6.5 which suggest only moderate risk in human when observed in dog and monkey. Notably, the Fletcher study did not use false positive and false negative results in its evaluation.
A recent study by Vargas found that QT interval data derived from relevant non-rodent models has a 90% chance of predicting QT findings in humans (Vargas et al., 2015) . This is consistent with our studies where the computed post-test odds for dog are 60%, and rabbit 83% which are much higher than the values for rat, 15%. The concordance for mouse to human was not statistically significant.
Another study performed by Mead et al. investigated the rodenthuman concordance of the Functional Observational Battery or the Irwin test in detail with strong statistical metrics. (Mead et al., 2016) . That work discussed the significant issue of interpreting animal behaviors that correspond to issues articulated by human patients. It also identified specific animal observations that correspond to human, namely nausea, dizziness, somnolence/fatigue, and pain. We used text mining of regulatory filings to look for animal observations that were deemed to correspond to those observations discussed by Mead. Table 12 shows the predictive value of those events for all species, and for rat and mouse. A set of related neurological events also appear in the list of low-predictive animal models in Table 8 . The overall conclusion from this analysis agrees with Mead that there is limited concordance for animal observations recorded in the Irwin test.
Pitfalls and limitations
As Mead et al. (2016) discuss, the interpretation of animal behaviors and assignment of a MedDRA preferred term to the observation can be difficult. PharmaPendium uses determinations of the authors of the report, or the curators assigned an observation from the reported symptoms. It is useful then to look at the underlying data in detail to understand the basis for the statistical results and identify errors in the data. Every data point in this study is connected to a specific statement in an indexed document that can be examined. Fig. 8 gives an example of the original text of a toxicology study with the conclusion of pain assigned by the authors based on their experience and the clinical signs (Teva Pharmaceuticals, 2010) . Fig. 9 is an example of reported animal behaviors that are interpreted by PharmaPendium curators as dizziness for the regulatory filing for oxycodone hydrochloride (Endo Pharmaceuticals, 2011). Fig. 10 is an example of interpretation of behavior as fatigue by the indexers of PharmaPendium (Cubist Pharmaceuticals, 2013) . In some cases there is ambiguity whether these behaviors should be categorized as somnolence or fatigue. The observation of somnolence is both statistically Fig. 7 . Preferred term animal-human concordance across species at 99.99% confidence level; TP > 4, LR+ ≥ 10. Line thickness is proportional to the likelihood ratio (LR+).
significant and predictive as shown in Table 12 . Monticello et al. (2017) sub-analyzed the influence of the animalhuman (Phase 1 only) exposure data on the false positive rate for liver toxicity for their 182 compound data set. The results of this study showed that higher exposures in animals lead to a higher false positive rate, indicating that the variables of dose and exposure are undoubtedly important. Nevertheless given above described pitfalls, we refrained from adding another variable to our analysis.
The methodology of this work has distinct limitations. It relies heavily on manual curation of regulatory reports and interpretation of data in reports to assign MedDRA vocabulary terms. The examples show that this can be subjective for some findings. The used MedDRA vocabulary is designed for human observations and diseases, which do not necessarily match with animal observations. Vice versa there are observations in animals which rarely are investigated in humans, e.g. histopathology of many organs and tissues. The assignment of MedDRA terms in the original reports can also be subjective, for example "Electrocardiogram QT prolonged" vs "Electrocardiogram QT corrected interval prolonged". ECG equipment often corrects the reported QT interval for heart rate during data collection.
Another caveat of our study is that the big data approach is agnostic with regard to the pharmacological relevance of the chosen nonclinical species. It is known from cardiovascular concordance studies (Ewart et al., 2014; Vargas et al., 2015) , that non-rodent species and particularly the telemetered dog show a good concordance with regard to QT interval changes, whereas the rat is known to be a less relevant species due to its difference in electrophysiology. Another example is the observation of "drug specific antibody present" for which the good concordance with human pharmacodynamics occurred for mice receiving surrogates or non-human primates (NHPs) receiving the human pharmaceutical (Bugelski and Martin, 2012) . These examples demonstrate that the pharmacological relevance or irrelevance of the nonclinical species can skew or strengthen the concordance analyses. However, we think the value of the agnostic big data approach precisely lies in the identification of a weak concordance for specific observations and individual nonclinical species, which subsequently may give raise to a hypothesis of lacking pharmacological relevance, meriting further mechanistic investigations. Enhanced mechanistic or pharmacological understanding over time will also lead to changes in the concordance analysis. For example QT investigations reported in approval documents were virtually inexistent before 1976 and peaked around 2011, i.e. concordance analyses within different time periods will result in different contingency values. We have added illustrative examples in the Supplementary Material.
Another reason why different publications on concordance analyses come to partly contradictory conclusions is the selected data set. At a first glance, it is striking how the authors of Olson et al. (2000) conclude that "these survey results support the value of in vivo toxicology studies to predict for many significant human toxicities associated with pharmaceuticals, whereas Bailey et al. (2014) summarize their study " … that results from tests on animals … are highly inconsistent predictors of toxic responses in humans, and are little better than what would result merely by chance." The conflicting positions are mainly due to the data underlying the different analyses. The data used in the Olson study covers drug candidates from clinical development phases I to III collected from the archives of 12 pharmaceutical companies. In 37% of the observed human toxicities these caused the termination of the project. These attritions are not evenly distributed over the organ classes as can be seen in Fig. 11 . The positive animal concordance (i.e. the ability to predict a human toxicity) is almost reciprocally related to the attrition, indicating that those human toxicities, which are less well predicted by animal studies lead more often to attrition particularly if the observed toxicity cannot be attributed to the primary pharmacology (e.g. liver or urinary system). Toxicities which affect vital organs, have a slow rate of reversibility (compared to gastrointestinal or hematologic disorders)and are difficult to monitor (e.g. kidney damage) lead more often to termination, if there is no relation to the primary drug action and thus no chance to avoid the adverse event by lowering the dose.
Overall the compilation in Fig. 11 demonstrates that preclinicalclinical data collections from drug development programs differ significantly from data compiled from sources of registered drugs, since certain toxicities are preferentially eliminated based on the criticality of the organ class and the lacking relation to primary pharmacology. On Table 9 Observations with low negative likelihood indicating that the lack of observation is predictive for safety. the other hand, data collections which include post-marketing data collected from pharmacovigilance reports such as used by Bailey et al., (2014) underlay the risk of over-reporting of human toxicities and confounders of co-morbidity which particularly affect the negative predictivity of animal studies. In addition, both data sets are influenced by factors of subjective manual curation as already discussed further above. It can be expected that the later problems will be overcome with the progression of controlled vocabularies and ontologies (CDISC-SEND) and the concomitant initiatives to enhance data collection and sharing, such as the Preclinical Safety Leadership Group (DruSafe) within The International Consortium for Innovation and Quality (IQ) in Pharmaceutical Development (Monticello, 2015) or the Innovative Medicines Initiative project eTransafe (www.etransafe.eu).
Conclusions
Using a big-data approach is a powerful analytic method, which produces a large body of analytic results, which are per se without preconception. We have shown both the principal feasibility of a combined text-mining and statistical approach but have also elaborated on a number of pitfalls such as lacking controlled vocabulary and insufficient alignment of preclinical-clinical ontologies. We highlighted the concordances with the highest numbers of TP together with the positive likelihood. The most concordant observations, namely cardiac effects such as QT prolongation and arrhythmia are consistent with previously published reports.
Our results contribute to answer the questions posed in the introduction:
• What is the implication biomedical of an observation in an animal for human risk?
The implicated human risk is unique to each animal-event pair. In general, many translations are confirmed as predictive, such as QT prolongation and other arrhythmias. Other pairs are statistically related but have low predictive value. This study has created a metric for each event-species pair that can be used to predict the human risk.
• Is the translation dependent on the animal species used?
The translatability is dependent on the species used for testing. In some cases, an observation has been made in several species, in others only one. However, because the particular species used for each test are biased it is not directly possible to determine which species is best from a biology viewpoint. However, it can be concluded from the TP and the LR + that the species selection for these specific endpoints results in predictive power confirming the value of the animal study for human risk assessment.
• Can the concordance be increased by looking at higher level groupings of the observations above the preferred term level?
Only in few cases the higher-level grouping resulted in meaningful results (e.g. application site reactions). However, grouping the reported preferred term (PT) level reports into higher levels of the MedDRA hierarchy sometimes includes such a variety of events that the additional false positives and negatives result in no statistical confidence in the relationship. As the data is grouped to higher levels the statistical significance tends to decrease.
The large-scale approach computes both statistical significance and predictive power. It is up to the researcher to define criteria for both values to address a particular issue. Many medically significant concordances are confirmed as having high significance and predictive power, particularly around cardiac events. On the other extreme, events can be identified that have been observed in animal, but never reported in human in regulatory studies, and events reported in human that have never been reported in animal studies. 
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